CDKN2A and cancer: We next compared the promoter activity of ERE73 (1 + 2) MT-ARF (−13) and ERE73 (3 + 4) MT-ARF (−13) with that of the ERE73 wild type in both HFFs and cancer cell lines (Saos-2, 5637, DLD-1, and HLF).